Pyrexar Medical was formed to take on the fight against cancer. We purchased the Hyperthermia product line from BSD Medical in April 2015. Our plan is to support the existing BSD-500 and BSD-2000 customers, continue to make product improvements, support the growth of Thermal Oncology and spread the word about this amazing cancer therapy.
Randomized clinical trials (RCT’s) have been shown significant improvement in clinical outcome when hyperthermia was added to radiotherapy and/or chemotherapy. In 2004 experts in clinical hyperthermia held a consensus meeting (Kadota Fund International Forum 2004) about the evidence of the published clinical results of the RCT’s. Level 1 evidence was found for bladder cancer, breast cancer, cervical cancer, cancer of the esophagus, lymph nodes of head and neck tumors, rectum cancer, soft tissue sarcoma, malignant melanoma, glioblastoma multiform, and various superficial cancers.
According to the standards set by the Society of Thermal Medicine (STM); European Society for Hyperthermic Oncology (ESHO) and the Asian Society of Hyperthermic Oncology (ASHO); the benefits of hyperthermia are fully realized when the tumor temperature reaches 39-43 degrees Celsius.
Heat is known to kill cancer cells, shrink tumor size, increase radiosensitivity, inhibit DNA repair, oxygenate hypoxic tumors, produce heat shock proteins and increase disease free survival.
An independent study published in the Journal of the American Medical Association (JAMA) reports on a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study. In addition to higher CR, the addition of hyperthermia increased the median long-term survival rate from 6.2 to 15.4 years
Countdown to the University of Maryland CME-Credited Thermal Oncology Educational Program, Oct 18-19. See Program Details